• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • Global health

    US announces support for HIV prevention game-changer with mixed reactions

    The announcement follows a commitment made by PEPFAR and the Global Fund last year to provide access to the twice-yearly HIV prevention injectable to 2 million people over three years.

    By Jenny Lei Ravelo // 05 September 2025

    Related Stories

    FDA approves new HIV prevention tool, though access questions linger
    FDA approves new HIV prevention tool, though access questions linger
    New partnerships bring price parity between lenacapavir and oral PrEP
    New partnerships bring price parity between lenacapavir and oral PrEP
    US aid cuts overshadow HIV research advances
    US aid cuts overshadow HIV research advances
    In Malawi, the fight to get HIV services back on track post-USAID cuts
    In Malawi, the fight to get HIV services back on track post-USAID cuts

    The U.S. Department of State on Thursday announced plans to bring lenacapavir — a potentially game-changing innovation for HIV prevention — to 2 million people by 2028.

    Through the U.S. President’s Emergency Plan for AIDS Relief, or PEPFAR, the State Department will partner with countries with the largest burden of HIV and AIDS “over the coming months to co-develop strategies for distributing lenacapavir, with a focus on preventing mother-to-child transmission,” according to the news release.

    Gilead Sciences, the company that developed the drug, is offering lenacapavir “at no profit” as part of the initiative, said its chairman and CEO, Daniel O’Day.

    This article is free to read - just register or sign in

    Access news, newsletters, events and more.

    Join usSign in

    Read more:

    ► US aid cuts overshadow HIV research advances

    ► Opinion: The US legacy in HIV is unraveling

    ► FDA approves new HIV prevention tool, though access questions linger

    • Global Health
    • Humanitarian Aid
    • U.S. President's Emergency Plan for AIDS Relief (PEPFAR)
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Jenny Lei Ravelo

      Jenny Lei Ravelo@JennyLeiRavelo

      Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.

    Search for articles

    Related Stories

    Global HealthFDA approves new HIV prevention tool, though access questions linger

    FDA approves new HIV prevention tool, though access questions linger

    Global healthNew partnerships bring price parity between lenacapavir and oral PrEP

    New partnerships bring price parity between lenacapavir and oral PrEP

    Global HealthUS aid cuts overshadow HIV research advances

    US aid cuts overshadow HIV research advances

    Global healthIn Malawi, the fight to get HIV services back on track post-USAID cuts

    In Malawi, the fight to get HIV services back on track post-USAID cuts

    Most Read

    • 1
      Revolutionizing lung cancer care and early screening in LMICs
    • 2
      Africa CDC chief: 60% of foreign health aid was effectively wasted
    • 3
      Opinion: An industry playbook for addressing NCDs in LMICs
    • 4
      Devex Dish: The World Bank plants a $9 billion-a-year seed
    • 5
      How local entrepreneurs are closing the NCD care gap in LMICs
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement